Skip to main content

Table 3 Direct UTI costs in France

From: The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey

  Estimated proportion of patients consuming at least one care modalityc Mean cost per care modalityc Societal cost (millions €) French National Health Insurance cost (millions €) Patient dost (before private complementary millions €)
All visits GP (after inclusion) 13 % (9–19 %) 23,72 (23,67–23,77) 23.0 14.5 8.5
Gynecologist 1 % (0.4–3 %) 40,68 (39,93–41,44)
Urologist 0.4 % (0.06–2 %) 56,71 (52,16–61,26)
Diagnostic tests Blood test 2.5 % (1–5 %) 13,50 (11,38–15,64) 9.6 6.0 3.6
Urine culture 24 % (18–31 %) 17,55d
Ultrasound 8 % (5–12 %) 67,29 (63,84–70,73)
Urology scan 0.3 % (0.1–2 %) 150,77
Prescription drugs Fosfomycin 39 % (30–49 %) 8.36d 10.5 6.1 4.4
Other antibiotica 64 % (55–73 %) 13.27 (12.37–14.17)
Analgesics 13 % (10–17 %) 3.98 (3.70–4.27)
Other prescriptionsb 4 % (2–8 %) 5.17 (4.39–5.95)
Hospitalization   0.06 % (0.01–1.2 %) 1294.67 0.9 0.7 0.2
  1. Sources: General Sample of Beneficiaries (EGB), Nomenclature of Medical Biology Acts (NABM) and Common Classification of Medical Acts (CCAM), drug base (base de medicaments) and MEDICAM
  2. euros
  3. aamoxicillin, amoxicillin – clavulanic acid, cefixime, cefpodoxime, ceftriaxone, ciproloxacine, enoxacine, lomefloxacin, nirofurantoin, norfloxacin, nystatin, oxfloxacin, pefloxacin, nalidixic acid, trimethoprim-sulphamethoxazole
  4. bAntifungals, digestive transit regulators, hormonal treatments, proton pump inhibitors with non-steroidal anti-inflammatory drugs and corticosteroids
  5. cEstimated proportion or mean cost (95 % CI, CI: confidence interval) with the sampling design
  6. dNo 95 % CI due to exact cost